-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the clinical trial application of the first class new drug HSK31858 of Haisco Pharmaceutical Group Co.
HSK31858 is an oral, potent and highly selective small molecule dipeptidyl peptidase 1 (DPP1) inhibitor independently developed by Haisco Pharmaceuticals.
It is worth mentioning that in August of this year, Haisco signed the "Technology Transfer Contract" with the company’s fourth-tier subsidiary HAISCO PHARMACEUTICALS PTE.
Neutrophils are the most common type of white blood cells and play an important role in pathogen destruction and inflammation regulation
In addition to HSK31858, AstraZeneca has also developed a DPP1 inhibitor-brensocatib (INS1007), but AstraZeneca paid a US$30 million down payment and a price of US$120 million in mileage in October 2016.
In September 2020, Insmed announced that the Phase 2 clinical study WILLOW of brensocatib in the treatment of non-cystic fibrosis bronchiectasis (NCFBE) reached the primary endpoint
In terms of safety, the most common adverse reactions in patients treated with brensocatib were cough, headache, increased sputum, dyspnea, exacerbation of infectious bronchiectasis, and diarrhea
In addition, it is worth mentioning that GSK terminated the development of the DPP1 inhibitor GSK-2793660 in 2015 due to concerns about the safety of long-term medication and some biological indicators have not been reached
The prevalence of bronchiectasis increases with age.
